List of Annovera drug patents

Annovera is owned by Therapeuticsmd Inc.

Annovera contains Ethinyl Estradiol; Segesterone Acetate.

Annovera has a total of 7 drug patents out of which 0 drug patents have expired.

Annovera was authorised for market use on 10 August, 2018.

Annovera is available in ring;vaginal dosage forms.

Annovera can be used as method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception, method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles.

Drug patent challenges can be filed against Annovera from August, 2022.

The generics of Annovera are possible to be released after 21 June, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles

Dosage: RING;VAGINAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in